© 2019 Helomics Corp. All rights reserved.

  • White Twitter Icon
  • Facebook - White Circle
  • White LinkedIn Icon

Helomics® Corporation Announces the Completion of the Third and Final Phase of its Corporate Restructuring Towards Becoming a Fully-Integrated Clinical Contract Research Organization

December 21, 2016


Corporate Restructuring includes a change of principle ownership and Gerald J. Vardzel, Jr. joins as the new President and CEO


PITTSBURGH – December 21, 2016 - Helomics® Corporation, a privately-held, healthcare company providing personalized medicine solutions for clients in the pharmaceutical, diagnostic, and biotech industries, today announced the completion of the final phase of its corporate realignment towards becoming a fully-integrated clinical contract research and clinical products organization (“ICCRO”).   


As an ICCRO, Helomics will provide product enhancement and clinical laboratory services, including comprehensive tumor profiling utilizing proprietary cell-based products and services, to strategic partners in the healthcare industries.  The new business model will continue to offer and enhance the Company’s clinical laboratory test menu, leveraging core scientific strengths, to provide physicians with relevant clinical information to better inform their patient treatment decisions.  Now, patients who consent to sample testing at Helomics have the opportunity to further cancer research and the development of new therapies and diagnostic methods through Helomics’ innovative technology development and industry partnerships. 


Gerald J. Vardzel Jr., will serve as the President and CEO.  With over 25 years of industry experience, Mr. Vardzel has guided many innovative products through validation and commercialization, perfecting tried and tested strategies in both start-up and established settings. Mr. Vardzel said, “It is a pleasure for me to serve in this leadership role for Helomics.  Helomics has a history of commitment to cutting-edge science to improve patient care.  This corporate realignment will allow us to focus on partnerships with pharmaceutical and diagnostic companies to enable innovative therapies and diagnostic technologies in the marketplace.”


About Helomics® Corporation

Helomics® is an integrated clinical contract research organization whose mission is to improve patient care by partnering with pharmaceutical, diagnostic, and academic organizations to bring innovative clinical products and technologies to the marketplace.  Helomics offers scientific and non-scientific product enhancement services and advanced clinical laboratory diagnostic tests to provide a customized solution to our client’s specific product development needs.

Helomics® is headquartered in Pittsburgh, Pennsylvania where the company maintains a state-of-the-art research laboratory and a CLIA-certified clinical laboratory. For more information please visit: www.helomics.com.


Safe Harbor Statement

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:  This news release may contain forward-looking information within the meaning of Section 27A Of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes”, “expects”, “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements.  



For more information, please contact:

Michelle Murgia, Marketing Communications and Design, Helomics Corp.





Source: Helomics® Corporation

Share on Facebook
Share on Twitter
Please reload

Featured Posts

Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis

September 10, 2019

Please reload

Recent Posts